BD's CentroVena One System Wins Key Vizient Innovative Technology Contract
BDX is trading near its 52-week low of $127.536 (10% above the low).
Summary
Becton Dickinson's CentroVena One™ Insertion System has been awarded an Innovative Technology contract by Vizient, a major healthcare performance improvement company. This contract provides BD with access to Vizient's extensive network, which represents over $156 billion in annual purchasing volume. The CentroVena One™ system is recognized for its innovative all-in-one design, simplifying central line placement by reducing procedural steps by 30% and procedure time by 50%. This validation and market access could significantly boost adoption and sales for the product, enhancing BD's competitive position in the medical device space.
At the time of this announcement, BDX was trading at $140.78 on NYSE in the Life Sciences sector, with a market capitalization of approximately $38.8B. The 52-week trading range was $127.54 to $187.35. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: PR Newswire.